



Deposited via The University of Sheffield.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/151687/>

Version: Accepted Version

---

**Proceedings Paper:**

El-Gheryani, M.S.A., Hoo, Z.H., Curley, R. et al. (2018) S136 Understanding longitudinal changes in %FEV1 variability and its role as an indicator of care quality among adults with cystic fibrosis. In: Thorax. British Thoracic Society Winter Meeting 2018, 05-07 Dec 2018, London, UK. BMJ Publishing Group, A85-A85. ISSN: 0040-6376. EISSN: 1468-3296.

<https://doi.org/10.1136/thorax-2018-212555.142>

---

© BMJ Publishing Group Ltd 2018. Reuse of this manuscript version (excluding any databases, tables, diagrams, photographs and other images or illustrative material included where a another copyright owner is identified) is permitted strictly pursuant to the terms of the Creative Commons Attribution-Non Commercial 4.0 International (CC-BY-NC 4.0) <https://creativecommons.org/licenses/by-nc/4.0/>

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new works must also acknowledge the authors and be non-commercial. You don't have to license any derivative works on the same terms. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.

## Understanding longitudinal changes in %FEV1 variability and its role as an indicator of care quality among adults with cystic fibrosis

### **Background:**

Cystic fibrosis (CF) is a long-term condition whereby regular nebulised medications are needed to maintain lung health. %FEV1 decline is traditionally used to indicate lung health, but it is relatively insensitive. %FEV1 decline tended to be preceded by %FEV1 variability, suggesting that it is potentially a more sensitive outcome measure. Given the consistent improvement in nebuliser adherence in Sheffield from 2013-2016, we hypothesised that %FEV1 variability would decrease over time.

### **Aim:**

To determine the year-by-year change in %FEV1 variability in the Sheffield Adult CF Centre from 2013-2016

### **Methods:**

FEV1 and other clinical data were retrospectively collected from every adult with CF receiving care in Sheffield from 2013-2016, excluding those who had lung transplantation or on ivacaftor. I-neb nebuliser data were used to calculate normative adherence.[1] %FEV1 was calculated using the GLI-2012 equation. %FEV1 variability was calculated as 'median deviation',[2] then categorised into 'high' (exceeds the ESCF 75<sup>th</sup> centile) vs 'low' (within the ESCF 75<sup>th</sup> centile). Due to non-normal distribution and presence of outliers, non-parametric methods were used for the summary measures and longitudinal comparisons.

### **Results:**

208 unique adults with CF provided data for this analysis. Nebuliser adherence increased consistently from 2013 (median 32.8%, IQR 14.5 to 58.1%) to 2016 (median 49.6%, IQR 21.9 to 68.9%), Friedman test p-value 0.004. The rate of %FEV1 decline slowed considerably from 2014-2015 (median -0.90%, IQR -3.25 to 1.46%) to 2015-2016 (median -0.32%, IQR -2.87 to 1.76%). This was preceded by a considerable drop in the proportion of people with high %FEV1 variability from 2014 (61/162, 37.7%) to 2015 (54/174, 31.0%). Results were summarised in Table 1.

### **Conclusion:**

These results highlight the potential of using %FEV1 variability to detect improvement in care quality before changes in %FEV1 decline are detected. Further studies are needed to better understand the factors that influence %FEV1 variability and determine the generalisability of these findings.

## References:

1. Hoo ZH, et al. Patient Prefer Adherence 2016;10:887-900.
2. Morgan WJ, et al. J Pediatr 2016;169:116-21.

**Table1: Summary of 2013-2016 findings**

	<b>2013</b> (n = 166)	<b>2014</b> (n = 170)	<b>2015</b> (n = 185)	<b>2016</b> (n = 186)	<b>P-value</b>
People on I-neb, n (%)	89 (53.6)	97 (57.1)	104 (56.2)	102 (54.8)	
% Adherence, median (IQR)	32.8 (14.5 – 58.1)	39.6 (14.6 – 65.4)	42.9 (18.6 – 73.8)	49.6 (21.9 – 68.9)	0.004 <sup>†</sup>
Annual intravenous antibiotics day, median (IQR)	14 (0 – 35)	14 (0 – 28)	14 (0 – 35)	14 (0 – 40)	0.001 <sup>†</sup>
BMI in kg/m <sup>2</sup> , median (IQR)	22.3 (19.7 – 24.6)	22.7 (20.0 – 25.0)	23.0 (20.3 – 26.0)	23.2 (20.4 – 26.0)	<0.001 <sup>†</sup>
% FEV <sub>1</sub> , median (IQR)	78.7 (54.1 – 92.5)	76.6 (54.4 – 89.7)	77.8 (60.4 – 89.0)	78.5 (58.5 – 89.6)	<0.001 <sup>†</sup>
% FEV <sub>1</sub> variability	(n = 161)	(n = 162)	(n = 174)	(n = 178)	
Median (IQR)	5.0 (2.7 – 8.5)	4.8 (2.8 – 7.5)	4.4 (2.6 – 7.1)	4.2 (2.5 – 7.0)	0.915 <sup>†</sup>
People exceeding 75 <sup>th</sup> centile, (%)	61 (37.9)	61 (37.7)	54 (31.0)	53 (29.8)	0.418 <sup>‡</sup>
Annual %FEV <sub>1</sub> change		(n = 158)	(n = 162)	(n = 176)	
Median (IQR)		-1.09 (-4.58 to 1.49)	-0.90 (-3.25 to 1.46)	-0.32 (-2.87 to 1.76)	0.135 <sup>†</sup>
People with decline >2%, (%)		69 (43.7)	63 (38.9)	56 (31.8)	0.139 <sup>‡</sup>

<sup>†</sup> Friedman test

<sup>‡</sup> Cochran's Q test